Mumbai, March 20 (Udaipur Kiran): Aurobindo Pharma is currently trading at Rs. 1281.90, up by 33.95 points or 2.72% from its previous closing of Rs. 1247.95 on the BSE.
The scrip opened at Rs. 1252.35 and has touched a high and low of Rs. 1287.50 and Rs. 1252.35 respectively. So far 15678 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1319.60 on 12-Mar-2026 and a 52 week low of Rs. 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1314.85 and Rs. 1240.40 respectively. The current market cap of the company is Rs. 74586.54 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.63% and 6.56% respectively.
Aurobindo Pharma’s wholly owned subsidiary — Apitoria Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-V, an API manufacturing facility situated at Telangana. The USFDA has classified the said facility as Voluntary Action Indicated (VAI) and this inspection is now closed.
The USFDA had conducted an inspection of the said facility from December 01 to December 12, 2025 and issued a ‘Form 483’ with 03 observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
